Cover Image
市場調查報告書

B型血友病:開發中產品分析

Hemophilia B - Pipeline Review, H1 2018

出版商 Global Markets Direct 商品編碼 232835
出版日期 內容資訊 英文 126 Pages
訂單完成後即時交付
價格
Back to Top
B型血友病:開發中產品分析 Hemophilia B - Pipeline Review, H1 2018
出版日期: 2018年03月20日 內容資訊: 英文 126 Pages
簡介

B型血友病,是由於血液凝固第九凝血因子的不足而產生,遺傳性的出血疾病。若沒有充分數量的第九凝血因子,無法使血液凝固有效堵住出血。主要症狀,有在關節內部的出血,伴隨關節痛、腫脹,紫斑,環狀切除伴隨的過剩出血,消化管、尿路的出血,鼻血等。主要的治療方法,有缺損的凝血因子的補充等。

本報告提供全球各國的B型血友病治療用的開發中產品的開發情形相關分析,產品開發、上市的最新趨勢,及臨床實驗的各階段的產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊,為您概述為以下內容。

目錄

簡介

  • 分析範圍

B型血友病概要

治療藥的開發

  • B型血友病開發中產品:概要
  • B型血友病開發中產品:各企業
  • B型血友病開發中產品:各大學/研究機關
  • B型血友病治療藥:開發中的產品一覽:各企業
  • B型血友病治療藥:各研究中的產品一覽:各大學/研究機關

B型血友病:治療藥的評估

  • 各標的
  • 各作用機制
  • 各投藥法
  • 各分子類型

B型血友病開發治療藥的企業

  • Alnylam Pharmaceuticals Inc
  • Amarna Therapeutics BV
  • Bayer AG
  • Bioverativ Inc
  • Catalyst Biosciences Inc
  • China Biologic Products Inc
  • CSL Ltd
  • Genethon SA
  • Green Cross Corp
  • LFB SA
  • MolMed SpA
  • Novo Nordisk A/S
  • OPKO Biologics Ltd
  • Pfizer Inc
  • Pharming Group NV
  • Promethera Biosciences SA
  • RegenxBio Inc
  • Sangamo Therapeutics Inc
  • Shire Plc
  • Spark Therapeutics Inc
  • UniQure NV

藥物簡介

B型血友病治療藥:開發暫停的產品

B型血友病治療藥:開發中止的產品

B型血友病相關產品的開發里程碑

  • 值得注意的最新趨勢、新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC10291IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hemophilia B - Pipeline Review, H1 2018, provides an overview of the Hemophilia B (Hematological Disorders) pipeline landscape.

Hemophilia B is a hereditary bleeding disorder caused by a lack of blood clotting factor IX. Symptoms include bleeding into joints and associated pain and swelling, bruising, excessive bleeding following circumcision, gastrointestinal tract and urinary tract hemorrhage and nosebleeds. Treatment includes replacing the defective clotting factor.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hemophilia B - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Hemophilia B (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hemophilia B (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hemophilia B and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 3, 10, 2, 11, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 4 and 1 molecules, respectively.

Hemophilia B (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hemophilia B (Hematological Disorders).
  • The pipeline guide reviews pipeline therapeutics for Hemophilia B (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hemophilia B (Hematological Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hemophilia B (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hemophilia B (Hematological Disorders)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hemophilia B (Hematological Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hemophilia B (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Hemophilia B - Overview
  • Hemophilia B - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Hemophilia B - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Hemophilia B - Companies Involved in Therapeutics Development
  • Alnylam Pharmaceuticals Inc
  • Amarna Therapeutics BV
  • Bayer AG
  • Bioverativ Inc
  • Catalyst Biosciences Inc
  • China Biologic Products Inc
  • CSL Ltd
  • Expression Therapeutics LLC
  • GC Pharma
  • Genethon SA
  • LFB SA
  • Logicbio Therapeutics Inc
  • MolMed SpA
  • Novo Nordisk AS
  • OPKO Biologics Ltd
  • Pfizer Inc
  • Pharming Group NV
  • Promethera Biosciences SA
  • RegenxBio Inc
  • Sangamo Therapeutics Inc
  • Shire Plc
  • Spark Therapeutics Inc
  • UniQure NV
  • Hemophilia B - Drug Profiles
  • AMT-060 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AMT-061 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BAX-335 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BAY-1093884 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BIVV-002 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CB-2679d - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Cell Therapy to Activate F9 for Hemophilia B - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • coagulation factor IX (human) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • concizumab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CSL-689 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • fidanacogene elaparvovec - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • fitusiran - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy for Hematological Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy for Hemophilia B - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy to Activate Coagulation Factor IX for Hemophilia B - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy to Activate Coagulation Factor IX for Hemophilia B - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy to Activate Coagulation Factor IX for Hemophilia B - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy to Activate Factor IX for Hemophilia B - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy to Activate Factor IX for Hemophilia B - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy to Activate Factor IX for Hemophilia B - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy to Activate Factor IX for Hemophilia B - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy to Activate Factor IX for Hemophilia B - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy to Activate Factor IX for Hemophilia B - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • HepaStem - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LR-769 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • marstacimab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • marzeptacog alfa - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MG-1113A - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • OPK-88005 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Recombinant Factor IX Replacement for Hemophilia B - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Recombinant Protein to Inhibit Coagulation Factor XIV for Hemophilia A and Hemophilia B - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SB-FIX - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SHP-648 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Stem Cell Therapy to Activate Coagulation Factor IX for Hemophilia B - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SVF-VIIa - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Hemophilia B - Dormant Projects
  • Hemophilia B - Discontinued Products
  • Hemophilia B - Product Development Milestones
  • Featured News & Press Releases
  • Feb 28, 2018: Sangamo Announces U.K. Authorization Of Clinical Trial Evaluating Zinc Finger Nuclease In Vivo Genome Editing Treatment For Hemophilia B
  • Feb 05, 2018: Spark Therapeutics to Present Data on its Hemophilia B Drug Candidate SPK-8011 in EAHAD Conference, Spain
  • Dec 15, 2017: FDA lifts clinical hold on fitusiran
  • Dec 11, 2017: New Data Show Extended Prophylactic Dosing with ALPROLIX Provides Safe and Effective Protection in People with Severe Hemophilia B
  • Dec 11, 2017: Spark Therapeutics and Pfizer Announce Longer-term Preliminary Data Showing Consistent and Sustained Factor IX Levels in Hemophilia B at 59th American Society of Hematology (ASH) Annual Meeting and Exposition
  • Dec 09, 2017: ALPROLIX Demonstrates Higher Tissue Distribution and Retention in Joints Compared to Other Factor IX Molecules in a Preclinical Imaging Study
  • Dec 06, 2017: One-dose gene therapy produces clotting factor, safely stops bleeding in hemophilia B patients
  • Dec 06, 2017: Spark Therapeutics and Pfizer Announce Publication in The New England Journal of Medicine of Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Hemophilia B
  • Dec 05, 2017: Spark Therapeutics Announces Presentation on Updated Hemophilia B Clinical Trial at 59th American Society of Hematology Annual Meeting and Exposition
  • Nov 27, 2017: U.S. Label Update for Bioverativs ALPROLIX Adds Data Reinforcing Efficacy and Safety of Long-Term Prophylactic Treatment in Adults, Adolescents and Children With Hemophilia B
  • Nov 09, 2017: Alnylam Announces Successful Outcome Following FDA Type A Meeting to Discuss Fitusiran Program in Hemophilia
  • Nov 01, 2017: Bioverativ to Present New Data on ALPROLIX at ASH 2017 Annual Meeting
  • Oct 25, 2017: Alprolix approved in the Kingdom of Saudi Arabia for the treatment of hemophilia B
  • Sep 07, 2017: Alnylam Provides Pipeline Update on Fitusiran Investigational RNAi Therapeutic Programs
  • Sep 07, 2017: Sanofi Alliance Partner Alnylam Provides Update on Fitusiran Development Program
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Hemophilia B, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Stage and Target, H1 2018
  • Number of Products by Stage and Mechanism of Action, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Hemophilia B - Pipeline by Alnylam Pharmaceuticals Inc, H1 2018
  • Hemophilia B - Pipeline by Amarna Therapeutics BV, H1 2018
  • Hemophilia B - Pipeline by Bayer AG, H1 2018
  • Hemophilia B - Pipeline by Bioverativ Inc, H1 2018
  • Hemophilia B - Pipeline by Catalyst Biosciences Inc, H1 2018
  • Hemophilia B - Pipeline by China Biologic Products Inc, H1 2018
  • Hemophilia B - Pipeline by CSL Ltd, H1 2018
  • Hemophilia B - Pipeline by Expression Therapeutics LLC, H1 2018
  • Hemophilia B - Pipeline by GC Pharma, H1 2018
  • Hemophilia B - Pipeline by Genethon SA, H1 2018
  • Hemophilia B - Pipeline by LFB SA, H1 2018
  • Hemophilia B - Pipeline by Logicbio Therapeutics Inc, H1 2018
  • Hemophilia B - Pipeline by MolMed SpA, H1 2018
  • Hemophilia B - Pipeline by Novo Nordisk AS, H1 2018
  • Hemophilia B - Pipeline by OPKO Biologics Ltd, H1 2018
  • Hemophilia B - Pipeline by Pfizer Inc, H1 2018
  • Hemophilia B - Pipeline by Pharming Group NV, H1 2018
  • Hemophilia B - Pipeline by Promethera Biosciences SA, H1 2018
  • Hemophilia B - Pipeline by RegenxBio Inc, H1 2018
  • Hemophilia B - Pipeline by Sangamo Therapeutics Inc, H1 2018
  • Hemophilia B - Pipeline by Shire Plc, H1 2018
  • Hemophilia B - Pipeline by Spark Therapeutics Inc, H1 2018
  • Hemophilia B - Pipeline by UniQure NV, H1 2018
  • Hemophilia B - Dormant Projects, H1 2018
  • Hemophilia B - Discontinued Products, H1 2018

List of Figures

  • Number of Products under Development for Hemophilia B, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Targets, H1 2018
  • Number of Products by Stage and Targets, H1 2018
  • Number of Products by Mechanism of Actions, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Routes of Administration, H1 2018
  • Number of Products by Stage and Routes of Administration, H1 2018
  • Number of Products by Molecule Types, H1 2018
  • Number of Products by Stage and Molecule Types, H1 2018
Back to Top